Drug watch.
Whitson
S
S
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000600:supply & distribution / Q000627:therapeutic use*; D053626:Atovaquone; D002109:Caffeic Acids; D003457:Cryptosporidiosis / Q000188:drug therapy; D004304:Dosage Forms; D017277:Drug Approval; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000600:supply & distribution / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D009285:Naphthoquinones; D009574:Nitro Compounds; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000188:drug therapy; D013386:Succinates / Q000627:therapeutic use; D013844:Thiazoles
D000981:Antiprotozoal Agents; D000998:Antiviral Agents; D002109:Caffeic Acids; D004304:Dosage Forms; D019428:HIV Integrase Inhibitors; D017320:HIV Protease Inhibitors; D016898:Interferon-alpha; D009285:Naphthoquinones; D009574:Nitro Compounds; D018894:Reverse Transcriptase Inhibitors; D013386:Succinates; D013844:Thiazoles; C100435:chicoric acid; C041747:nitazoxanide; D053626:Atovaquone